1. Taiwan Stocks

  2. •

    Health technology

  3. •

    Medical specialties
Diamond Biotechnology Co., Ltd.

Diamond Biotechnology Co., Ltd.

TTPEX:6815
21.50
TWD
-0.05
(-0.23%)
1.13BMarket Cap
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
9.06
9.33
8.87
8.61
10.75
11.83
16.79
19.88
12.7
- -
Basic EPS, GAAP
1.99
1.69
1.46
0.31
1.14
0.91
1.27
1.89
-1.78
- -
Free Cash Flow per Basic Share
-2.9
0.87
0.15
0.4
-0.52
2.3
-4.24
0.24
-0.08
- -
Dividend per Share
0.11
0.5
1.2
0.82
0.03
0.1
0.08
0.13
0.17
- -
Book Value per Share
4.45
5.24
6.81
6.32
7.43
8.24
9.42
15.75
13.72
14.56
Tangible Book Value per Share
3.46
4.38
6.05
5.67
6.93
7.89
9.21
15.66
13.69
14.54
Basic Weighted Avg Shares
21
24
30
36
37
37
37
39
39
39
Sales/Revenue/Turnover
193
227
268
306
395
435
616
768
501
- -
Operating Margin (%)
28.23
24.68
21.39
4.37
12.17
10.82
10.61
14.68
-14.79
- -
Depreciation Expense
16
20
32
55
58
53
50
28
29
- -
Net Income, GAAP
42
41
44
11
42
33
47
73
-70
- -
Effective Tax Rate (%)
18.36
21.68
21.86
18.19
19.46
20.17
19.87
23.5
- -
- -
Profit Margin (%)
21.94
18.09
16.46
3.61
10.61
7.68
7.59
9.53
-14.02
- -
Working Capital
65
95
124
114
155
67
132
479
347
385
LT Debt
24
22
96
74
67
25
186
222
174
170
Total Equity
164
193
250
232
273
303
346
623
542
575
Return on Invested Capital (%)
- -
19.26
13.7
3.08
9.04
7.37
8.21
10.3
- -
- -
Return on Capital (%)
- -
19.13
14.33
3.33
10.46
7.49
8.67
10.03
- -
- -
Return on Common Equity (%)
- -
23.04
19.95
4.58
16.59
11.6
14.4
15.1
-12.07
- -

Capital Structure

TWD

•

in mil. unless spec.
Jun'25
Dec'25
Jun'26
ST Debt
60
60
34
LT Borrowings
185
172
167
LT Finance Leases
4
2
4
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
39
39
39
Market Capitalization
1,860
2,488
1,128

Working Capital

TWD

•

in mil. unless spec.
Jun'25
Dec'25
Jun'26
Total Current Assets
621
500
505
Cash, Cash Equivalents & STI
205
210
250
Accounts Receivable, Net
188
115
110
Inventories
118
92
80
Total Current Liabilities
175
153
120
Payables & Accruals
- -
- -
- -
ST Debt
60
60
34
Deferred Revenue
- -
- -
- -

Growth Rates

TWD

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
21.94%
-13.04%
Free Cash Flow
- -
-260.04%
-135.36%
Net Income, GAAP
- -
31.92%
-196.06%
Sales/Revenue/Turnover
- -
14.14%
-34.72%
Total Cash Common Dividend
- -
52.52%
32.69%

Semi-annual Revenue

TWD

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
768
2025
- -
- -
501
2026
- -
- -
- -

Semi-annual Earnings Per Share

TWD

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
1.89
2025
- -
- -
-1.78
2026
- -
- -
- -

Semi-annual Dividends Per Share

TWD

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
0.13
2025
- -
- -
0.17
2026
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Chia Hsien Hsieh
Full Time Employees
45
Sector
Health technology
Industry
Medical specialties
Address
No. 95, Sec. 1 New Taipei TP Taiwan 221
IPO Date
Jan 29, 2021
Website
diamond-biotechnology.com
Similar Companies
Intuitive Surgical, Inc. (NASDAQ:ISRG)
Boston Scientific Corporation (NYSE:BSX)
Thermo Fisher Scientific Inc (NYSE:TMO)
Illumina, Inc. (NASDAQ:ILMN)
Abbott Laboratories (NYSE:ABT)
GRAIL, Inc. (NASDAQ:GRAL)
Business
Diamond Biotechnology Co., Ltd researches, develops, manufactures and sells medical equipment and skincare products primarily in Taiwan and internationally. The company offers skincare products under the Timera and Diamond Beauty brands, including facial masks, lotions, creams and essences for skin care and cleaning; medical equipment such as wires, sonic wave devices, radio wave equipment, frozen fat reduction systems and micro plastic surgery consumables including botulinum and collagen injections for wrinkle and sagging improvement; leasing services for medical equipment; and medical beauty management consulting. Founded in 2014 and headquartered at 14F, No. 95, Sec. 1, Xintai 5th Rd., Xizhi Dist., New Taipei City, Taiwan, it targets hospitals, clinics and open channels in the biotechnology and medical care industry. In March 2025, the company launched Ronkyla chin filler injection featuring MIT technology in partnership with Tai Zhong to target the NT$7 billion lipolysis market. It listed on the Taipei Exchange in January 2021 under ticker 6815.TWO with paid-in capital of NT$247.8 million.